339 related articles for article (PubMed ID: 17442002)
1. Pharmacokinetics of levetiracetam in infants and young children with epilepsy.
Glauser TA; Mitchell WG; Weinstock A; Bebin M; Chen D; Coupez R; Stockis A; Lu ZS
Epilepsia; 2007 Jun; 48(6):1117-22. PubMed ID: 17442002
[TBL] [Abstract][Full Text] [Related]
2. Prospective assessment of levetiracetam pharmacokinetics during dose escalation in 4- to 12-year-old children with partial-onset seizures on concomitant carbamazepine or valproate.
Fountain NB; Conry JA; Rodríguez-Leyva I; Gutierrez-Moctezuma J; Salas E; Coupez R; Stockis A; Lu ZS
Epilepsy Res; 2007 Apr; 74(1):60-9. PubMed ID: 17270398
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of levetiracetam and dosing recommendation in children with epilepsy.
Chhun S; Jullien V; Rey E; Dulac O; Chiron C; Pons G
Epilepsia; 2009 May; 50(5):1150-7. PubMed ID: 19175400
[TBL] [Abstract][Full Text] [Related]
4. Levetiracetam: relative bioavailability and bioequivalence of a 10% oral solution (750 mg) and 750-mg tablets.
Coupez R; Straetemans R; Sehgal G; Stockis A; Lu ZS
J Clin Pharmacol; 2003 Dec; 43(12):1370-6. PubMed ID: 14615473
[TBL] [Abstract][Full Text] [Related]
5. Influence of enzyme inducing antiepileptic drugs on the pharmacokinetics of levetiracetam in patients with epilepsy.
Freitas-Lima P; Alexandre V; Pereira LR; Feletti F; Perucca E; Sakamoto AC
Epilepsy Res; 2011 Mar; 94(1-2):117-20. PubMed ID: 21282041
[TBL] [Abstract][Full Text] [Related]
6. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy.
Perucca E; Cloyd J; Critchley D; Fuseau E
Epilepsia; 2008 Jul; 49(7):1123-41. PubMed ID: 18503564
[TBL] [Abstract][Full Text] [Related]
7. Modeling and simulation of intravenous levetiracetam pharmacokinetic profiles in children to evaluate dose adaptation rules.
Snoeck E; Jacqmin P; Sargentini-Maier ML; Stockis A
Epilepsy Res; 2007 Sep; 76(2-3):140-7. PubMed ID: 17851036
[TBL] [Abstract][Full Text] [Related]
8. Intravenous levetiracetam in children with seizures: a prospective safety study.
Ng YT; Hastriter EV; Cardenas JF; Khoury EM; Chapman KE
J Child Neurol; 2010 May; 25(5):551-5. PubMed ID: 20413804
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of levetiracetam in children with epilepsy younger than 2 years of age.
Krief P; Li Kan ; Maytal J
J Child Neurol; 2008 May; 23(5):582-4. PubMed ID: 18448575
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic study of levetiracetam in children.
Pellock JM; Glauser TA; Bebin EM; Fountain NB; Ritter FJ; Coupez RM; Shields WD
Epilepsia; 2001 Dec; 42(12):1574-9. PubMed ID: 11879369
[TBL] [Abstract][Full Text] [Related]
11. Age and comedications influence levetiracetam pharmacokinetics in children.
Dahlin MG; Wide K; Ohman I
Pediatr Neurol; 2010 Oct; 43(4):231-5. PubMed ID: 20837299
[TBL] [Abstract][Full Text] [Related]
12. Adjunctive levetiracetam in infants and young children with refractory partial-onset seizures.
Piña-Garza JE; Nordli DR; Rating D; Yang H; Schiemann-Delgado J; Duncan B;
Epilepsia; 2009 May; 50(5):1141-9. PubMed ID: 19243423
[TBL] [Abstract][Full Text] [Related]
13. Tolerability and efficacy of oral loading of levetiracetam.
Koubeissi MZ; Amina S; Pita I; Bergey GK; Werz MA
Neurology; 2008 May; 70(22 Pt 2):2166-70. PubMed ID: 18505995
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic variability of four newer antiepileptic drugs, lamotrigine, levetiracetam, oxcarbazepine, and topiramate: a comparison of the impact of age and comedication.
Johannessen Landmark C; Baftiu A; Tysse I; Valsø B; Larsson PG; Rytter E; Johannessen SI
Ther Drug Monit; 2012 Aug; 34(4):440-5. PubMed ID: 22777154
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of levetiracetam after oral and intravenous administration of a single dose to clinically normal cats.
Carnes MB; Axlund TW; Boothe DM
Am J Vet Res; 2011 Sep; 72(9):1247-52. PubMed ID: 21879984
[TBL] [Abstract][Full Text] [Related]
16. Effect of age and comedication on levetiracetam pharmacokinetics and tolerability.
Hirsch LJ; Arif H; Buchsbaum R; Weintraub D; Lee J; Chang JT; Resor SR; Bazil CW
Epilepsia; 2007 Jul; 48(7):1351-9. PubMed ID: 17573925
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of levetiracetam in patients with moderate to severe liver cirrhosis (Child-Pugh classes A, B, and C): characterization by dynamic liver function tests.
Brockmöller J; Thomsen T; Wittstock M; Coupez R; Lochs H; Roots I
Clin Pharmacol Ther; 2005 Jun; 77(6):529-41. PubMed ID: 15961984
[TBL] [Abstract][Full Text] [Related]
18. Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study.
Ramael S; Daoust A; Otoul C; Toublanc N; Troenaru M; Lu ZS; Stockis A
Epilepsia; 2006 Jul; 47(7):1128-35. PubMed ID: 16886975
[TBL] [Abstract][Full Text] [Related]
19. Levetiracetam as an adjunct to phenobarbital treatment in cats with suspected idiopathic epilepsy.
Bailey KS; Dewey CW; Boothe DM; Barone G; Kortz GD
J Am Vet Med Assoc; 2008 Mar; 232(6):867-72. PubMed ID: 18341442
[TBL] [Abstract][Full Text] [Related]
20. Levetiracetam as add-on therapy for idiopathic generalized epilepsy syndromes with onset during adolescence: analysis of two randomized, double-blind, placebo-controlled studies.
Rosenfeld WE; Benbadis S; Edrich P; Tassinari CA; Hirsch E
Epilepsy Res; 2009 Jul; 85(1):72-80. PubMed ID: 19327967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
